Objective. To compare the degree of pain relief between high-dose (40 mg of triamcinolone acetonide) and low-dose (20 mg of triamcinolone acetonide) corticosteroid injections in patients with severe pain due to adhesive capsulitis.
Introduction
Adhesive capsulitis is a common disease, manifesting with pain and limited motion of the affected shoulder. The condition results from fibrosis of the capsule of the glenohumeral joint, which causes pain and stiffness. Various treatment options have been attempted to treat this condition, for example, rest, nonsteroidal antiinflammatory drugs, stretching exercise, intra-articular steroid injection, and arthrographic distension and manipulation under anesthesia [1] [2] [3] . Among them, intraarticular corticosteroid injection has been reported to be an effective method to reduce pain and to increase the range of motion rapidly, particularly in the first six weeks [4, 5] . Although corticosteroid injection has been considered an effective method by many clinicians, there is little information about its efficacy related to dose dependency. Physicians select the regimen of injection based on their personal experience rather than scientific evidence. There have been two previous studies to determine the optimal dose of triamcinolone acetonide, which is widely used for intra-articular corticosteroid injection into various joints, including the glenohumeral joint. One of the previous studies reported that when comparing high-dose (40 mg of triamcinolone acetonide) and low-dose (10 mg of triamcinolone acetonide) injection, high-dose injection was more effective in relieving pain [6] . However, 10 mg of triamcinolone acetonide is too low to be used as a low-dose regimen because most authors and guidelines recommend a minimum of 20 mg of triamcinolone acetonide for intra-articular shoulder injection [7] . Another recent study was conducted to determine the optimal dose of corticosteroid injection for treating adhesive capsulitis, using 20 mg and 40 mg of triamcinolone acetonide [8] . The authors concluded that there was no significant difference in the improvement of clinical symptoms between the two doses, and they suggested the use of a low dose (20 mg of triamcinolone acetonide). However, this study also had the limitation that the patients had a lower degree of initial pain on the average visual analog scale (VAS). This mild initial pain might easily reach a ceiling effect to improve the pain with a low dose of corticosteroid injection. It is difficult to apply this result directly to the clinical field because in the clinical field intra-articular injection is usually performed in patients with severe pain. If the study had been conducted in more severely affected patients for determination of the optimal corticosteroid dose, the conclusion could have been different. If this conclusion were different in patients with more severe pain, 20 mg of triamcinolone acetonide injection should not be administered because it would not achieve an adequate effect to relieve acute severe pain. However, if this conclusion were the same, 20-mg injection must be considered because possible side effects of steroids are related to the dose [9] [10] [11] [12] [13] [14] [15] . We hypothesized that in patients with severe pain, a high-dose corticosteroid injection (40 mg of triamcinolone acetonide) would be more effective in relieving pain caused by adhesive capsulitis than a low-dose corticosteroid injection (20 mg of triamcinolone acetonide). The aim of this study is to compare the degree of pain relief between high-dose (40 mg of triamcinolone acetonide) and low-dose (20 mg of triamcinolone acetonide) corticosteroid injection in patients with severe pain due to adhesive capsulitis.
Methods

Participants
We recruited patients who visited our outpatient clinics from November 2014 to July 2016 and were diagnosed with adhesive capsulitis. Inclusion criteria were clinical diagnosis of adhesive capsulitis, age 20 to 70 years, and pain of severe intensity, defined as a score of 8 or more points on a numeric rating scale (NRS). Adhesive capsulitis was diagnosed when the x-ray and ultrasound of the shoulder were normal and limitation of the range of motion with pain was observed. An NRS score higher than 8 was selected for inclusion criteria because a previous study defined an NRS score of 8 as the optimal cutoff point between moderate and severe pain [16] . We used NRS for pain assessment, instead of VAS, in our study. Based on our review on pain assessment tools, it can be suggested that it is easier to assess the expression of pain severity on NRS and it has more sensitivity than VAS [17] . In addition, NRS is highly correlated with VAS, and it shows a higher score while assessing changes in pain [18] .
Exclusion criteria were previous surgery or history of trauma to the shoulder area in the three months before the visit, rotator cuff tear on ultrasound examination, cognitive impairment with inability to express the severity of pain properly, recent one-month history of corticosteroid injection in the affected shoulder, recent two-week history of taking an oral corticosteroid, evidence of infection in blood laboratory results (erythrocyte sedimentation rate > 40 mm/h or c-reactive protein > 10 mg/dl), leukocytopenia (white blood cell < 2,000/mL), taking an immunosuppressive drug or antitumor agent, and evidence of bleeding tendency in blood laboratory results (international normalized ratio > 2.0, aPTT > 80 sec, platelet < 50,000).
Design and Randomization
This study was conducted as a prospective, randomized, double-blind, dose-comparative trial. After screening and evaluation, patients were randomly assigned into two groups, the high-dose group (40 mg of triamcinolone acetonide) and the low-dose group (20 mg of triamcinolone acetonide), with a 1:1 allocation ratio, via block randomization with a block size of four by residents of physical medicine and rehabilitation. Physical examination was conducted by a senior resident who had four years' experience in physical medicine and rehabilitation. Ultrasound examinations were conducted by a single experienced physiatrist who had experience treating more than 10,000 cases and was blinded to group allocation. According to the groups to which the patients were allocated, they received injections of 40 mg or 20 mg of triamcinolone acetonide (Tamceton, HanAll BioPharma Co. Ltd., Seoul, Korea) mixed with 4 mL of 1% lidocaine from the same physiatrist under ultrasound guidance via the posterior approach, as described in a previous study [19] . Patients did not know to which group they belonged. During the study period, patients were prohibited from taking pain killers, receiving physical modalities, and receiving additional injections except when they complained of severe pain.
Sample Size
The required sample size was calculated based on a previous study of intra-articular injection for treatment of adhesive capsulitis [8] . Mean pain intensity scores in the low-dose injection group (20 mg of triamcinolone acetonide) and high-dose injection group (40 mg of triamcinolone acetonide) were 3.12 and 4.93, respectively, and the mean change in the NRS score between the lowdose and high-dose treatment groups was 1.81. The estimated standard deviation of the patient population was 2.13. Considering an a-error of 0.05 and a b-error of 0.1, the minimum sample size needed was 14.5 for each group.
Outcome Measurements
Clinical outcomes were evaluated before and three weeks after the injection by the same physiatrist who was blinded to the group allocation. The primary outcome was NRS for the shoulder pain intensity, and the secondary outcomes were the Shoulder Pain and Disability Index (SPADI) and the passive range of motion (PROM) in four directions; flexion, abduction, external rotation, and internal rotation. The degree of PROM was determined when the patient felt severe pain during the PROM procedure.
Statistics SPSS 22.0 software (SPSS Inc, Chicago, IL, USA) was used for the statistical analysis. Age and sex distribution between the two groups were compared using the independent t test and chi-square test. The changes in NRS, SPADI, and PROMs after the injection between the two groups were analyzed using the Mann-Whitney U test. The primary statistical analysis was based on the intention-to-treat principle using the improvement of the NRS at three weeks after the injection as the primary end point. The missing data were managed using the last-observation-carried-forward technique. P values of less than 0.05 were considered statistically significant.
We obtained oral and written informed consent from all patients. All protocols were approved by our Institutional Review Board (Approval Number: 2014-10-047 and 2015-12-152).
Results
A total of 32 patients were recruited, and they were randomly assigned into two groups, the high-dose group (40 mg of triamcinolone acetonide) and the low-dose group (20 mg of triamcinolone acetonide). Table 1 summarizes baseline characteristics of the patients, and there was no significant difference in age or gender distribution between the two groups. Symptom duration was 2.4 6 2.0 months in the low-dose group and 3.3 6 2.4 months in the high-dose group, indicating that all patients were in the acute inflammatory phase of adhesive capsulitis. Six patients in the low-dose group had underlying diseases. One patient had hypertension, two patients had diabetes, two patients had cancer (prostate, cholangiocarcinoma), and one patient had heart failure. Five patients in the high-dose group had underlying diseases. Two out of the five patients had hypertension, one patient had right breast cancer, one patient had multiple myeloma, and one patient had Sjogren disease. All patients in both groups did not take immunosuppressants.
All patients received low and high doses of triamcinolone acetonide injection in each group, and two patients in the low-dose group were lost to follow-up. The data of two patients were managed using the lastobservation-carried-forward technique. Figure 1 illustrates the CONSORT diagram.
The initial NRS scores were 8.7 in the low-dose group and 8.7 in the high-dose group, which were not significantly different (P ¼ 1.00). Three weeks after the injection, the NRS score showed significant improvement in both groups (P ¼ 0.01 in both the low-dose group and the high-dose group) (Figure 2 ), but there was no statistically significant difference between the two groups (P ¼ 0.63).
Initial SPADI scores did not show any significant group difference (P ¼ 0.65). SPADI score significantly improved at three weeks after the injection in both groups (P ¼ 0.02 in the low-dose group and P < 0.01 in the high-dose group) (Figure 2 ), but a group difference was not observed (95% confidence interval ¼ -37.24 to 1.04, P ¼ 0.06).
Initial PROMs for flexion, abduction, internal rotation, and external rotation did not show any significant group difference. The change of PROM in four directions after the injection did not show any significant difference between low-and high-dose groups (P ¼ 0.91 in flexion, P ¼ 0.77 in abduction, P ¼ 0.22 in internal rotation, and P ¼ 0.44 in external rotation). Figure 3 shows changes in PROMs in four directions.
Discussion
We found that there were no significant differences in pain, range of motion, or SPADI score after three weeks of injection between the high-dose (40 mg of triamcinolone acetonide) and low-dose (20 mg of triamcinolone acetonide) steroid injection groups. Patients in both groups achieved acute significant symptom relief compared with the initial state. Our study demonstrated that 20 mg of triamcinolone acetonide injection into the glenohumeral joint was sufficient to elicit acute symptom relief in adhesive capsulitis with severe pain.
Our result is consistent with that of a previous study, which was conducted in patients with mild adhesive capsulitis [8] . Therefore, 20 mg of triamcinolone acetonide is sufficient for treating adhesive capsulitis irrespective of the initial pain severity. Our results provide scientific evidence for physicians to inject 20 mg of triamcinolone acetonide initially in patients with adhesive capsulitis who have severe symptoms. Therefore, 20 mg of triamcinolone acetonide can be recommended initially without any concern regarding whether 20 mg of triamcinolone acetonide is an adequate dose.
The patients in our study had an average of 2.9 months of symptom duration, which means that most of the patients were in the acute inflammatory phase of adhesive capsulitis. We performed outcome measurement only once (at three weeks) because we focused on the effect of steroid dose on acute pain relief in patients with adhesive capsulitis. Considering the clinical course of intra-articular injections, a three-week follow-up period is enough to identify rapid response to injection [4] . In most clinical studies on adhesive capsulitis, clinical assessment was performed in the first one to six weeks [4] , and hence, we used three weeks as the clinical assessment time point. Considering that the purpose of intra-articular injection is to improve the symptoms in a short-term period, follow-up at three weeks after injection is meaningful.
We demonstrated that anti-inflammatory action of 20 mg of triamcinolone in the glenohumeral joint was enough.
Arroll et al. [20] demonstrated that 20 mg of triamcinolone was efficacious in achieving pain control in the knee joint at two weeks. Considering that the volume of the glenohumeral joint space is approximately 22.5 mL [21] and it can be reduced to 7 mL in adhesive capsulitis, while the volume of the knee joint space is 131 mL [22] , 20 mg of triamcinolone was considered sufficient to control the inflammatory reaction in the glenohumeral joint.
The exact molecular mechanism of the antiinflammatory action of corticosteroids has not been unveiled, but corticosteroids facilitate the function of the anti-inflammatory protein by activating glucocorticoid receptors and inhibiting the function of inflammatory mediators including cytokines, chemokines, adhesion molecules, arachidonic acid, and platelet activating factor [23] . We think that this activity shows an effect above the minimal threshold level of amounts, rather than according to the doses. Therefore, we thought that if the dose of the injected steroid were greater than the minimum dose necessary to eliminate the inflammatory reaction, then the steroid would show enough effect on pain reduction irrespective of its dose.
The half-life of triamcinolone acetonide in the joint cavity is determined to represent the absorption phase rather Figure 3 Changes of passive range of motion for flexion, abduction, internal rotation, and external rotation before and three weeks after the injection are presented. Bar means one standard deviation.
than the elimination phase, so the half-life is affected by the loading dose [24] . Therefore, the steroid dose injected into the joint cavity is important in the success of treatment. We did not investigate the pharmacokinetics of triamcinolone in our study, but more than 20 mg would be enough to show the anti-inflammatory action irrespective of the half-life.
The side effects of steroid injection include tendon rupture and prolonged increase in glucose level in diabetic patients [14] . In addition, triamcinolone was reported to have a chondrotoxic effect and inhibitory activity against human tenocytes causing suppression of collagen synthesis in vitro [10, 15] . There were several comments suggesting that steroid dose can have a positive correlation with the incidence of infection [9] , weight gain [13] , and avascular necrosis of bone [11] . Also, the length of time on steroids, the relative potency of the glucocorticoid, and the absolute dose all play a role in the occurrence of steroid-induced diabetes mellitus [12] . Therefore, our study has an important conclusion, that the use of 20 mg of steroid is recommended to manage adhesive capsulitis with severe pain, rather than 40 mg of steroid, which is the usual dose in the clinical situation.
We did not investigate 10 mg or less than 20 mg of triamcinolone in this study because we were not certain that 20 mg of triamcinolone would be effective in adhesive capsulitis with severe pain at the time of study design. Considering that a 10-mg steroid injection did not show much improvement of pain (initial VAS of about 6) from De Jong's study [6] , the optimal dose in adhesive capsulitis should be between 10 mg and 20 mg.
Two patients in the low-dose group were lost to followup. One patient was a 66-year-old woman. Her initial NRS was 9, she had a SPADI score of 51.5, and the initial range of motion (ROM) was 90 degrees of flexion, 90 degrees of abduction, 70 degrees of internal rotation, and 70 degrees of external rotation. The other patient was a 53-year-old man. His initial NRS was 8, his SPADI score was 54.6, and the initial ROM was 170 degrees of flexion, 120 degrees of abduction, 90 degrees of internal rotation, and 90 degrees of external rotation. Both of them denied any specific underlying disease except for shoulder pain caused by adhesive capsulitis, and they did not complain of any discomfort immediately after the injection, but they did not visit our outpatient clinic at the scheduled time. We supposed that they felt no improvement after steroid injection, and we managed their data using the last-observationcarried-forward technique (data before the injection) based on the technique of handling missing data in randomized controlled trials [25] . When we performed two other statistical methods for missing data to prevent statistical errors, the same conclusion was derived. We omitted their data from the analysis (per prototol analysis), and we found that our results did not change (P ¼ 0.69 in NRS and P ¼ 0.07 in SPADI). When we performed the statistics with use of worst-case analysis (managing the two lost data as the worst results within the group), the results did not change (P ¼ 0.64 in NRS and P ¼ 0.08 in SPADI).
There are several limitations to our study. Even though we calculated the required sample size based on the results of a previous study, 16 patients in each group might be a small sample size. Future studies with bigger sample sizes will consolidate our results.
In conclusion, an injection of 20 mg of triamcinolone acetonide into the glenohumeral joint is sufficient to elicit rapid symptom relief in patients with severe adhesive capsulitis; hence, 20 mg of triamcinolone acetonide must be recommended initially in patients with adhesive capsulitis irrespective of the initial pain severity.
